Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide.
These stocks are moving in today's session Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's uncover which stocks are experiencing notable gaps during today's session. The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy' Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops The company said it plans to investigate a positive signal from female patients.
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and updates are anticipated.
